Ivabradine Use and Dosing in Heart Failure with Reduced Ejection Fraction
Primary Recommendation
Ivabradine should be initiated at 5 mg twice daily with food in patients with symptomatic chronic HFrEF (LVEF ≤35%) who remain in sinus rhythm with resting heart rate ≥70 bpm despite maximally tolerated beta-blocker therapy. 1, 2
Patient Selection Criteria
Before considering ivabradine, confirm ALL of the following:
- LVEF ≤35% documented on echocardiography
- Sinus rhythm (not atrial fibrillation)
- Resting heart rate ≥70 bpm at rest
- NYHA Class II-III symptoms despite guideline-directed medical therapy
- Maximally tolerated beta-blocker dose already achieved (this is critical—beta-blockers have proven mortality benefit; ivabradine does not) 1
- Stable for ≥4 weeks on current GDMT regimen
Critical caveat: Only 25% of patients in the pivotal SHIFT trial were on optimal beta-blocker doses. The mortality benefit of beta-blockers is well-established, so you must uptitrate beta-blockers to maximum tolerated dose before adding ivabradine. 1
Dosing Algorithm
Initial Dosing
Standard patients: Start 5 mg twice daily with food 2
High-risk patients (history of conduction defects, elderly >70 years, impaired renal function, low lean body mass, or those where bradycardia could cause hemodynamic compromise): Start 2.5 mg twice daily 2
Dose Titration (Assess after 2 weeks, then ongoing)
| Resting Heart Rate | Action |
|---|---|
| >60 bpm | Increase by 2.5 mg twice daily (maximum 7.5 mg twice daily) |
| 50-60 bpm | Maintain current dose (target range achieved) |
| <50 bpm or symptomatic bradycardia | Decrease by 2.5 mg twice daily; if already on 2.5 mg twice daily, discontinue |
Target heart rate: 50-60 bpm at rest 2
Absolute Contraindications
Do NOT use ivabradine if any of the following are present:
- Acute decompensated heart failure
- Clinically significant hypotension
- Sick sinus syndrome, sinoatrial block, or 3rd-degree AV block (unless functioning pacemaker present)
- Clinically significant bradycardia
- Severe hepatic impairment
- Pacemaker dependence
- Concomitant strong CYP3A4 inhibitors (ketoconazole, clarithromycin, nefazodone, ritonavir, nelfinavir)
Expected Clinical Benefits
Primary benefit: Reduction in heart failure hospitalizations (this was the main driver of benefit in SHIFT) 1
Secondary benefit: Modest reduction in cardiovascular death when combined with HF hospitalization as composite endpoint 1
Important limitation: Ivabradine does NOT reduce mortality as a standalone endpoint—its benefit is primarily in reducing HF hospitalizations. This differs from beta-blockers, ACE inhibitors, ARBs, ARNI, and MRAs which have mortality benefits. 1
Monitoring Requirements
- Regularly monitor cardiac rhythm for development of atrial fibrillation (5.0% per patient-year risk vs 3.9% with placebo) 2
- Discontinue immediately if atrial fibrillation develops 2
- Monitor for bradycardia (6.0% per patient-year; 2.7% symptomatic) 2
- Assess resting heart rate at each visit and adjust dose accordingly
Real-World Application
In well-managed HFrEF populations where GDMT is properly optimized, only approximately 17% of patients will ultimately meet criteria for ivabradine therapy. 3 This underscores that ivabradine is an adjunctive therapy for a specific subset of patients, not a first-line agent.
The key clinical pearl: Ivabradine is for patients who have already maximized all other GDMT (beta-blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) but still have elevated heart rate ≥70 bpm and persistent symptoms. It fills a gap but does not replace foundational HF therapies with mortality benefit.